Lung Cancer, Sarcopenia
Conditions
Keywords
soy protein, whey protein, lung cancer related sarcopenia
Brief summary
Sarcopenia is common in lung cancer patients. It is one of the significant factors affecting the overall survival, radiotherapy and chemotherapy efficacy, and quality of life of patients with lung cancer. Previous studies have shown that increased protein intake can stimulate postprandial muscle synthesis, and improve muscle mass, strength, function, and overall survival. However, most previous studies have focused on the intervention of whey protein, while the protective effect of soybean protein on lung cancer-related sarcopenia (LCRS) has not yet been fully explored and reached an agreement. So, this study aims to explore the effects of soy and whey protein on muscle, gut microbiota, and clinical outcomes among patients with lung cancer-related sarcopenia, to provide a reference for further nutrition treatment.
Detailed description
This study will last 6 months. For the duration of the study, an anticipated total of 90 participants will be randomly assigned to receive either a 30-gram protein supplement or a placebo daily. There will be a total of 5 study visits, and dietary records, questionnaires, blood and stool collection, and functional testing will occur at all study visits. Intention-to-treat analysis (ITT) and per-protocol analysis (PP) will be conducted in statistical analysis.
Interventions
DIETARY_SUPPLEMENTsoy protein
The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
DIETARY_SUPPLEMENTwhey protein
The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
DIETARY_SUPPLEMENTplacebo
The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age\>=18years old * Patients with lung cancer and sarcopenia * ECOG\<=2 * Patients are able to provide written informed consent.
Exclusion criteria
* People who are allergic to soy protein and whey protein. * Participants received any drugs or supplements known to influence effcet size, such as protein powder, anabolic steroids, or glucorticosteroid before the 3 months preceding the study. * Participants with gastrointestinal bleeding, enterotomy or gastric bypass surgery before the 3 months preceding the study. * Concurrent severe cardiac disease, liver and renal failure, which may significantly interfere with study compliance. * Participants with electronic or mental device.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Appendicular skeletal muscle mass index at 3 months | 3 months | Defined as muscle mass (Unit: kg/m2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline physical performance Baseline at 3 months | 3 months | Measured by Short Physical Performance Battery (0-12) with higher scores meaning better physical performance. |
| Change from Baseline Physical function at 3 months | 3 months | Measured by FRAIL scale (0-5) with higher scores meaning better physical function. |
| Change from Baseline Quality of life questionnaire at 3 months | 3 months | Measured by EuroQol- 5 Dimension scale (0-5) with higher scores meaning better Quality of life. |
| Change from Baseline Hand grip at 3 months | 3 months | Defined as muscle strength (Unit: kg) |
| Number of patients with good Chemotherapy Tolerance | 3 months | Completing initially planned chemotherapy course is defined as good tolerance; dose adjustment, delayed completion or interruption of treatment are considered as poor tolerance. |
| Incidence of Chemotherapy toxicity | 3 months | Measured after initiation of chemotherapy using the WHO Toxicity Grades (gradeI-IV) with higher grades neaning severer chemotheraphy toxicity. |
| Change from Baseline gut microbiota composition at 3 months | 3 months | The stool samples of participants before and after intervention were collected and analized by 16S rRNA. |
Countries
China
Contacts
Primary ContactKang Yu, MD
Backup ContactYu Zang, MD
Outcome results
None listed